A detailed history of Soleus Capital Management, L.P. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Soleus Capital Management, L.P. holds 216,979 shares of KRYS stock, worth $33.2 Million. This represents 3.35% of its overall portfolio holdings.

Number of Shares
216,979
Previous 126,000 72.21%
Holding current value
$33.2 Million
Previous $23.1 Million 70.53%
% of portfolio
3.35%
Previous 2.34%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$174.7 - $213.66 $15.9 Million - $19.4 Million
90,979 Added 72.21%
216,979 $39.5 Million
Q2 2024

Aug 14, 2024

BUY
$153.12 - $183.64 $6.42 Million - $7.69 Million
41,900 Added 49.82%
126,000 $23.1 Million
Q1 2024

May 15, 2024

BUY
$108.01 - $179.35 $4.76 Million - $7.91 Million
44,100 Added 110.25%
84,100 $15 Million
Q4 2023

Feb 14, 2024

SELL
$96.0 - $128.29 $7.48 Million - $9.99 Million
-77,892 Reduced 66.07%
40,000 $4.96 Million
Q3 2023

Nov 14, 2023

BUY
$108.51 - $130.22 $835,527 - $1 Million
7,700 Added 6.99%
117,892 $13.7 Million
Q2 2023

Aug 14, 2023

BUY
$78.48 - $130.32 $1.96 Million - $3.26 Million
25,013 Added 29.37%
110,192 $12.9 Million
Q1 2023

May 15, 2023

SELL
$72.39 - $84.27 $7.46 Million - $8.68 Million
-103,038 Reduced 54.74%
85,179 $6.82 Million
Q4 2022

Feb 14, 2023

SELL
$63.14 - $79.9 $1.21 Million - $1.53 Million
-19,115 Reduced 9.22%
188,217 $14.9 Million
Q3 2022

Nov 14, 2022

SELL
$64.85 - $82.4 $463,677 - $589,160
-7,150 Reduced 3.33%
207,332 $14.5 Million
Q2 2022

Aug 15, 2022

SELL
$48.93 - $73.47 $3.66 Million - $5.5 Million
-74,855 Reduced 25.87%
214,482 $14.1 Million
Q1 2022

May 16, 2022

BUY
$51.99 - $72.11 $3.17 Million - $4.39 Million
60,900 Added 26.66%
289,337 $19.3 Million
Q4 2021

Feb 14, 2022

BUY
$39.81 - $88.24 $4.1 Million - $9.08 Million
102,908 Added 81.98%
228,437 $16 Million
Q3 2021

Nov 15, 2021

BUY
$52.01 - $71.77 $3.02 Million - $4.16 Million
58,000 Added 85.89%
125,529 $6.55 Million
Q2 2021

Aug 16, 2021

SELL
$62.14 - $81.82 $6.17 Million - $8.13 Million
-99,315 Reduced 59.53%
67,529 $4.59 Million
Q1 2021

May 17, 2021

BUY
$59.42 - $85.46 $9.29 Million - $13.4 Million
156,421 Added 1500.73%
166,844 $12.9 Million
Q4 2020

Feb 16, 2021

BUY
$40.64 - $61.38 $423,590 - $639,763
10,423 New
10,423 $625,000

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $3.92B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Soleus Capital Management, L.P. Portfolio

Follow Soleus Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Soleus Capital Management, L.P. with notifications on news.